Rituximab Phase IIIb Open-label, Multi-centre Assessment of Safety and Effectiveness in Patients With RA Following an Inadequate Response to One Prior Anti-TNF Inhibitor (RESET)
Phase of Trial: Phase III
Latest Information Update: 16 May 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms RESET
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 26 May 2010 Status changed from active, no longer recruiting to completed as reported by Roche website.
- 29 May 2007 New trial record.